🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT03441971
Active, not recruiting Not applicable

Evaluation of the GORE PV1 Device in Patients With Pulmonary Valve Dysfunction

NCT03441971 · tracked via the Priya Life Science USA tracker
Sponsor
W.L.Gore & Associates
Phase
Not applicable
Started
2018-06-07
Last updated
2026-02-05

Condition(s) studied

Heart Defects, CongenitalTetralogy of FallotPulmonary Valve InsufficiencyPulmonary Valve Stenosis

Investigational drug(s) / intervention(s)

GORE PV1

GORE PV1: Implantation of GORE PV1 Device for procedure to replace the pulmonary valve and reconstruct the right ventricular outflow tract (RVOT).

Study summary

This study will assess the safety and performance of the GORE PV1 Device for replacement of the pulmonary valve and reconstruction of the Right Ventricular Outflow Tract (RVOT).

Eligibility

Sex
ALL
Min age
5 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. A symptomatic or appropriate asymptomatic subject with a native or repaired right ventricular outflow tract requiring reconstruction with a valved conduit 2. Age ≥5 years at the time of informed consent signature. Note: Additional Inclusion Criteria may apply Exclusion Criteria: 1. An artificial valve at another position or will need an artificial valve at another position (i.e. replacement at the time of index procedure or anticipated within 3 years). 2. Subjects with previously implanted pacemaker (including defibrillators). 3. Major or progressive non-cardiac disease (liver failure, renal failure, cancer) that has a life expectancy of less than one year. Note: Additional Exclusion Criteria may apply

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Lurie Children's Hospital Chicago Illinois
Boston Children's Hospital Boston Massachusetts
Nationwide Children's Hospital Columbus Ohio
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03441971 on ClinicalTrials.gov ↗ ← All trials in the USA